Draxis begins studies for DVT tracer

Article

A subsidiary of Canadian pharmaceutical company Draxis Health of Mississauga, Ontario, has begun phase I clinical trials of Fibrimage, a peptide-based agent for the detection of deep vein thrombosis (DVT). If it reaches the market, Fibrimage could be a

A subsidiary of Canadian pharmaceutical company Draxis Health of Mississauga, Ontario, has begun phase I clinical trials of Fibrimage, a peptide-based agent for the detection of deep vein thrombosis (DVT). If it reaches the market, Fibrimage could be a competitor to Diatide's AcuTect peptide-based radiopharmaceutical, which is also targeted at DVT.

Draxis acquired rights to Fibrimage through its purchase of the radiopharmaceutical business of Merck Frosst Canada, which licensed the polypeptide that forms the basis of the agent from Bio-Technology General of Iselin, NJ. Draxis renamed the Merck Frosst Canada unit Draximage and made it one of four Draxis business units.

In addition to developing Fibrimage, Draximage sells radiopharmaceuticals in ready-to-use forms for the treatment and diagnosis of thyroid gland disorders and kidney and lung function. It also sells freeze-dried non-radioactive kits for the diagnosis of inflammatory and neoplastic bone disease and kidney and lung ventilation studies.

Fibrimage is based on fibrin binding domain (FBD), a recombinant polypeptide with a high binding affinity for fibrin, the primary component of a venous thrombus. FBD, which was developed by Bio-Technology General, is a lyophilized (freeze-dried) kit that is labeled with technetium-99m prior to use with a labeling process that was developed by the Merck Frosst Canada unit before its acquisition by Draxis.

The phase I study of Fibrimage should be completed by the fourth quarter, with a phase II study to begin shortly thereafter. Draximage believes the technology could be an alternative to contrast venography and Doppler ultrasound for the detection of DVT.

Recent Videos
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
Related Content
© 2025 MJH Life Sciences

All rights reserved.